1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
- Read more in our News Archive
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
I have a 16 yr Old friend that is 22 weeks pregnant and has aml. They have told her to terminate the pregnancy , deliver at 24 weeks or go to full term and not have the treatment until baby is born. Can anyone give me some info, support etc for her Many thanks Kat
The following information should not replace the assessment and advice you have been receiving from your physician (cancer specialist, obstetrician, or any other healthcare provider). It is offered for your information only. Consult your physician.
There is very little data regarding AML during pregnancy, most information is regarding ALL. However, in a large series from Japan, the authors could not find any adverse effects of ALL on pregnancy during late pregnancy (Int J Hematol 1998;67:37-43).
A case report of a 23 year old female diagnosed with AML at 23 weeks who received combined chemotherapy for treatment of the cancer, her child was delivered with no congenital abnormalities and follow-up at 5 years showed no neurologic or hematologic abnormalities (Int J Gynecol Obstet 1994;44:273-277).
In general, chemoptherapuetic agents cannot cause malformations beyond the first trimester and fetal toxicity has rarely been described.
There are numerous treatment options available, and it is important to discuss the safety of administering them during pregnancy with the physician or oncologist. It is important that the patient be closely followed by her physician throughout the pregnancy.